| Assessment Status |
Assessment process complete |
| HTA ID |
- |
| Drug |
Ledipasvir/sofosbuvir |
| Brand |
Harvoni® |
| Indication |
For the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4) in adults. |
| Rapid review commissioned |
14/11/2014 |
| Rapid review completed |
18/12/2014 |
| Rapid review outcome |
Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE |
18/03/2015 |
| NCPE assessment completed |
20/11/2015 |
| NCPE assessment outcome |
Reimbursement Recommended for Genotype 1 and 4. |
